implanted into nude mice at various stages of chondrogenic differentiation, formed interconnected bone trabeculae only when they had developed in vitro hypertrophic tissue structures. Advanced maturation in vitro resulted in accelerated formation of larger bony tissues. The underlying morphogenetic process was structurally and molecularly similar to the temporal and spatial progression of limb bone development in embryos. In particular, Indian
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INTRODUCTION
Endochondral ossification, namely the formation of bone tissue by replacement of cartilage templates, is the route through which long bones and the axial skeleton are formed in developing embryos (1) . This process relies on the highly specialized morpho-regulatory functions of hypertrophic chondrocytes (2) . Hypertrophic chondrocytes derive from the initial condensation of mesenchymal precursors and begin to produce a type X collagen-rich avascular cartilaginous matrix. At the periphery of this cartilage tissue, the so called "borderline" hypertrophic chondrocytes (3) instruct surrounding mesenchymal cells to differentiate into osteoblasts, which results in formation of the typical "bony collar". In parallel, chondrocytes in the central regions direct mineralization of the hypertrophic cartilage by initiating remodeling via the production of specific matrix metalloproteinases (MMP) and attract blood vessels by releasing vascular-endothelial growth factor (VEGF). The in-growing blood vessels deliver osteoblastic, osteoclastic and hematopoietic precursors, which mediate resorption of the deposited cartilaginous template and formation of vascularized bone tissue containing the so-called stromal sinusoids, which provide the microenvironment for hematopoiesis (1) .
Mesenchymal stem/stromal cells (MSC) from human adults have the ability to generate bone tissue in a variety of experimental models (4) , and hold great potential for bone repair in regenerative medicine. Thus far, MSC have been shown to generate bone tissue exclusively through direct osteogenic differentiation (i.e. in a manner akin to intra-membranous ossification), using a mineralized surface as "priming" substrate, with the exception of implantation in confined environments that prevent blood vessel invasion (e.g. diffusion chambers; ref. 5, 6) . This approach has already been used for a few clinical trials (7), but has not been effective for wide-spread clinical application (4) . The possibility to engineer MSCbased grafts that would recapitulate the morphogenetic processes and endochondral 4 ossification occurring during embryonic skeletal bone development would represent an important step forward for physiological bone repair, in line with the recently defined "developmental engineering" concepts (8) . In particular, the proposed route to bone formation through cartilage remodeling and vascularisation, which is also activated during successful, natural bone fracture repair, would potentially allow to overcome issues critical to the physiological functioning of engineered bone grafts, such as osteogenic performance, resistance to hypoxic conditions and efficiency of engraftment. So far, evidence of ectopic bone tissue morphogenesis via formation of hypertrophic cartilage templates have been reported for murine embryonic stem cells (ESC) (9) and chick embryonic mesenchymal cells (10) , but the paradigm has thus far not been reproduced using human ESC or clinically potentially more relevant sources such as adult human MSC (9) . The present study aimed at establishing and characterizing an endochondral bone tissue engineering approach, which uses bone marrow-derived, human adult MSC. By analogy to embryonic development of long bones, we hypothesized that the stage of cartilage hypertrophy reached in vitro by MSC would critically impact on the process of endochondral ossification following implantation into the nude mouse model. Our results demonstrate that engineered human hypertrophic cartilaginous tissue have the potential to undergo developmental changes similar to the ones during limb formation. Therefore, this study paves the way towards a "developmental engineering" approach for the regeneration of bone.
RESULTS
In vitro maturation of engineered hypertrophic cartilage tissues
Since endochondral bone formation is initiated by condensation and chondrogenic differentiation of mesenchymal cells, we cultured human adult MSC in a transwell, scaffoldfree system to maximize cell-cell interactions (11), using a serum-free medium supplemented with TGFβ1 as a potent inducer of chondrogenesis (12) . After one week, the resulting tissues had deposited a loose extracellular matrix, which was faintly positive for glycosaminoglycans (GAG). These specimens will be hereafter referred to as "pre-chondrogenic" tissues. After 2 weeks, the resulting tissues displayed clear cartilaginous features, including positive Safranin-O staining for GAG (Fig. 1a ) and large cells in lacunae embedded in abundant matrix (positive for type II collagen; Fig. 1c ). As only low and localized levels of type X collagen, which marks hypertrophic chondrocytes, were detected (Fig. 1e) , these specimens will be hereafter referred to as "early hypertrophic" tissues. At this stage, type I collagen was detected throughout the tissue (Fig. 1g) , with staining intensity increased in the outer rim. In this outer rim, low levels of bone sialoprotein (BSP) were also detected (Fig. 1i ), but no sign of matrix mineralization was apparent (Fig. 1k) .
In order to induce a more mature hypertrophic phenotype in human MSC, cells were cultured for 3 weeks in chondrogenic medium as described above and then for a further 2 weeks in medium lacking TGFβ1, but supplemented with β-glycerophosphate and l-thyroxin (13, 14) .
This culture protocol maintained the chondrogenic features, namely GAG and type II collagen expression (Fig. 1b, 1d ), but also promoted abundant and widespread accumulation of type X collagen (Fig. 1f) . The outer rim of the specimens was uniformly positive for type I collagen ( Fig. 1h) and developed a distinct mineralized collar (Fig. 1l) , strongly positive for BSP (Fig.   1j ). This histological pattern is characteristic of what was previously defined as "chondroosseous rudiment" (15) , and therefore specimens at this stage will be hereafter referred to as "late hypertrophic" tissues. The progression of chondrogenesis through hypertrophy and mineralization between 2 and 5 weeks of in vitro culture was paralleled by increased expression of type X collagen (CX; 4.2-fold), MMP13 (3.7-fold), core-binding factor alpha subunit 1 (Cbfa1; 7.2-fold), osteocalcin (OC; 430-fold), and bone sialoprotein (BSP; 5.7-fold) transcripts (Fig. 1m, 1n) . Following hypertrophic differentiation, phenotypic analysis by cell flow cytometry demonstrated an overall decrease in the expression of markers typical for undifferentiated MSC (CD73, CD90, CD105, CD146) and an increase of alkaline phosphatase 6 (ALP; Fig. S1 ). Vascular endothelial growth factor (VEGF) transcript, released protein and matrix-bound protein were detected at similar levels throughout the culture stages (Fig. S2) .
Progression of bone development following in vivo implantation of hypertrophic cartilage constructs
Both pre-chondrogenic, early hypertrophic and late hypertrophic constructs were implanted subcutaneously into nude mice and harvested after 4 and 8 weeks. Pre-chondrogenic constructs could not be recovered following implantation, as they were likely resorbed by the host environment. Following 4 weeks in vivo, early hypertrophic samples developed into structures containing cells embedded in large lacunae within an extracellular matrix rich in GAG ( Fig. 2a ) and type X collagen ( Fig. 2e ), while BSP deposition was confined in the outer rim ( Fig. 2i ). Eight weeks after implantation, the extracellular matrix extensively remodeled, displayed reduced GAG levels ( Fig. 2b ) and diffuse deposition of BSP (including the central regions, Fig. 2j ). In the central region BSP overlapped with type X collagen (compare Fig. 2j to Fig. 2f ). Four weeks after implantation, late hypertrophic samples displayed two distinct regions: an outer osteoid tissue, which resembled a bony collar, and an inner cartilaginous region, which was faintly positive for GAG (Fig. 2c ). Type X collagen was present predominantly in the peri-cellular space (Fig. 2g) , partially overlapping the accumulation of BSP (Fig. 2k ). After 8 weeks in vivo, the cartilaginous template was almost completely resorbed, and bone ossicles appeared also in the central region (Fig. 2d, 2h, 2l ).
Taken together, these results indicate that (i) a hypertrophic cartilaginous template is required to prime the endochondral ossification process, and (ii) the maturation of early hypertrophic samples toward the endochondral route progresses upon in vivo implantation, albeit it being delayed in comparison to implantation of late hypertrophic tissues.
In vivo remodeling and vascularisation of late hypertrophic cartilage
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To assess if the progression of tissue morphogenesis in vivo closely resembled normal endochondral ossification, late hypertrophic specimens were analyzed in more detail. Four weeks after implantation, the outer regions corresponding to the bony collar were positive for MMP-13 ( Fig. 3a) , which is typically expressed by late hypertrophic chondrocytes or osteoblasts and acts upstream of initiating angiogenesis (16) . Indeed, capillary vessels positive for CD31 (PECAM-1) began to penetrate the outer matrix (Fig. 3b, 3c) , consistent with the requirement to transport host osteoclasts, nutrients and pro-apoptotic signals to the internal hypertrophic cartilaginous template (1, 17) . After 8 weeks in vivo, cartilaginous regions undergoing remodeling were surrounded by multi-nucleated cells of the osteoclastic lineage, as revealed by their positive staining for two markers typically expressed at this stage of resorption (18), namely tartrate-resistant acid phosphatase (TRAP; Fig. 3d ) and MMP-9 ( Fig.   3e ). The ongoing, active matrix digestion process was confirmed by abundant expression of the so-called cryptic epitope of aggrecan (DIPEN; Fig. 3f ), which is exposed specifically upon MMP-mediated cleavage of aggrecan (19) .
Activation of signalling pathways involved in normal endochondral ossification
We next performed a real-time RT-PCR and in situ hybridization (ISH) analysis of the expression of key components of signalling pathways, which are known to be required for normal endochondral ossification during embryonic development (20, 21, 22) . In particular, the expression of Indian Hedgehog (IHH) as upstream signal, its receptor Patched1 (PTCH1) and GLI1 as mediator of IHH signal transduction was assessed. As expected, all these genes were either not expressed or expressed at very low levels in post-expanded MSC, while their expression levels were markedly increased in the early hypertrophic and even more in the late hypertrophic constructs (IHH: 5.2 fold, PTCH1: 3.0 fold, GLI1: 7.8-fold -when comparing late to early hypertrophic tissues; Fig. 4a ). In contrast, the expression of the other two Hedgehog ligands present in vertebrate species including humans (Sonic Hedgehog: SHH and 8 Desert hedgehog: DHH) was not activated (Fig. 4a) (Fig. 4a) . This shows that the progression towards endochondral ossification, both in vitro and in vivo, is paralleled by the activation and/or upregulation of the key signalling pathways involved in endochondral bone formation during embryonic limb skeletal morphogenesis (Fig. 4a-4d, Fig. S3 ). The human specificity of the ISH probes further allows to conclude that implanted cartilaginous templates included not only cells which provided signals initiating endochondral ossification (i.e., IHH), but also cells which responded to such signals (i.e., by expressing GLI1), and thus activated the required morphogenetic pathways (i.e., by expression of BMP-7). The functional importance of IHH signal transduction was further evidenced by the fact that its selective inhibition by cyclopamine administration (23) to in vitro cultured cartilaginous templates derived from human MSC completely blocked their morphogenesis and maturation (Fig. 4e, f, g ).
Characterization and quantification of the engineered endochondral bone tissue
Quantitative microtomography (μCT) of explants confirmed that deposition of mineralized matrix in early hypertrophic samples was negligible at 4 weeks after implantation and remained confined to the outer rim at 8 weeks (Fig. 5a, b) . In contrast, late hypertrophic constructs contained abundant peripheral mineral deposits already at 4 weeks and displayed an interconnected network of trabeculae throughout the core at 8 weeks after implantation (Fig. 5c, d) . Not only the quantity (Fig. 5e) , but also the stage of maturation of the mineralized matrix was more advanced in late hypertrophic tissues, as revealed by the significantly higher mineral density (Fig. 5f ) at both time points and by the lamellar morphology of the osteoid (Fig. 5g, h ). The complete loss of type X collagen in the lamellar structures of late hypertrophic tissues after 8 weeks in vivo contrasted with the remaining expression and partial 9 overlap with osteocalcin in the early hypertrophic constructs (Fig. 5i, j) . This result indicates that shortened maturation in vitro may delay progression of endochondral ossification in vivo.
To further investigate whether prolonged maturation in vivo would be able to compensate for shorter periods of in vitro culture, early hypertrophic constructs were analyzed 11 weeks after implantation, which results in a total period of in vitro and in vivo development equal to late hypertrophic samples analyzed 8 weeks after implantation. Interestingly, early hypertrophic samples analyzed after 11 weeks displayed features of mature bone formation, although they remained significantly smaller than late hypertrophic constructs after 8 weeks of implantation (Fig. S4) . It is currently debated whether the bone formed by endochondral ossification is exclusively generated by osteoblastic progenitors delivered by the vasculature or also by cells within the hypertrophic cartilaginous template (15) . We thus assessed our explants by ISH for the presence of human Alu repeat sequences. The presence of positive cells within the trabeculae of the bone and the surrounding soft tissue demonstrates an active contribution of the human MSC in the newly formed bone tissue and thus an effective intrinsic osteogenic property of the engineered grafts (Fig. 5k, l) . Due to the non-clonality of the original human MSC population, our results are however not conclusive with respect to the controversial issue whether bone cells derive by direct phenotypic conversion of hypertrophic chondrocytes or by direct osteoblastic differentiation of different MSC subsets (15) . Endochondral skeletogenesis is known to generate a marrow microenvironment, which is prerequisite for hematopoiesis (24) . Morphological analysis provided evidence for hematopoietic foci in some areas neighboring the bone matrix generated by the human adult MSC (Fig. S5a) , which further validates the endochondral ossification process. Support for possibly ongoing hematopoiesis in these foci was provided by the presence of CD146+ stromal cells (25), which were detected in the tissue constructs (Fig. S5b) .
DISCUSSION
In this study, we report a hitherto not described capacity of adult expanded human MSC to Interestingly, the progression of bone formation in vivo was regulated by the developmental stage and size of the hypertrophic cartilaginous constructs generated in vitro for implantation.
The need for a fine coordination between the stage of hypertrophy reached in vitro and the time required to achieve endochondral ossification in vivo is further confirmed by the reported absence of 'frank' trabecular bone tissue in a previous study where chondrogenically differentiated human MSC were implanted ectopically (27) .
The ectopic, "inert" subcutaneous implantation model used for this study allowed us to demonstrate that the hypertrophic cartilaginous constructs contained all necessary "biological instructions" to initiate a developmental process with similarities to what is observed during limb skeletal bone development (i.e. activation and up-regulation of IHH, BMP and PTHLH signalling, and self-organization of the tissue in a spatially and temporally coordinated manner). The experimental concept described here is in line with the ideas of "developmental engineering", in that an engineered construct is able to progress through development and differentiation into a structured tissue in a manner comparable to normal progression of embryonic development (28) . In particular, no instructive external signals seem required after implantation and MSC were able to form bone tissue without a ceramic/mineral substrate, which is typically necessary to 'prime' differentiation into functional osteoblasts (6, 29) . This may open the possibility either to use the tissue itself as a scaffold (this study) or -in case a predefined size and shape is required -to introduce different types of materials (e.g. synthetic polymers) with can be easier processed or tailored with respect to their physical and/or mechanical properties and could be better biodegradable than ceramic scaffolds (30) .
By mimicking normal developmental processes during bone engineering and repair, the endochondral route of MSC differentiation into bone we describe here could provide significant biological and practical advantages in comparison to engineering approaches relying on intra-membranous ossification. For example, implantation of a hypertrophic cartilage template in contrast to a construct delivering undifferentiated MSC or osteoblasts, may be better suited to overcome the initial lack of vascularisation and associated hypoxia. In fact, hypertrophic chondrocytes can accelerate graft invasion by blood vessels (e.g. by release of angiogenic factors and production of MMPs) and are physiologically functional even at reduced oxygen tension (31) . Moreover, considering the different composition and metabolism of bone tissues formed by intra-membranous and endochondral morphogenesis (32) , and the concept that bone repair processes should avoid major differences with normal developmental programs (33), MSC-driven bone formation via endochondral ossification could lead to more successful engraftment. Our study warrants further investigations towards a clinical implementation of the developed paradigm, including (i) scaling-up of the constructs implanted and (ii) orthotopic implantation in an immunocompetent animal model as biomechanical and inflammatory/immune mechanisms likely participate in regulating the bone forming potential of the hypertrophic templates. Finally, it will be interesting to assess the contribution of host cells in the observed processes, possibly in immunocompetent models (34), and if hypertrophic cartilage constructs without cells might be able to initiate endochondral ossification by recruiting host progenitors. Experiments in this direction would open the attractive possibility to manufacture biological off-the-shelf grafts relying on the properties of a cell-laid extracellular matrix.
In conclusion, we describe the first model based on human adult MSC, which recapitulates certain aspects of normal endochondral bone formation during embryonic development. The model system described is of clinical relevance for bone engineering and/or regeneration. Furthermore, it can be used to study the cellular/molecular mechanisms that control endochondral bone formation by human adult MSC isolated from both normal individuals and patients affected by specific diseases.
MATERIALS AND METHODS
All human samples were collected with informed consent of the involved individuals and all mouse experiments were performed in accordance with Swiss law. All studies were approved by the responsible veterinary and ethics authorities. Human mesenchymal stem cells (MSC) were expanded for 2 passages and cultured in transwell (5x10 5 cells/insert) for 1 week or 2 weeks in a chondrogenic medium (with TGFβ1; "pre-chondrogenic" and "early hypertrophic" respectively), or for 3 weeks in chondrogenic medium followed by 2 weeks in a hypertrophic medium (without TGFβ1 and with beta-glycerophosphate and thyroxine; "late 
